SELLAS Life Sciences (SLS) is rated 'Hold' due to pending phase 3 REGAL data for GPS in AML after CR2, a major 2026 catalyst.

PacBio’s Compatible partner program recognizes third-party providers whose solutions have been evaluated to work seamlessly with PacBio instruments and data formats. As a named partner, Lucid Genomics ...

Amid rising demand for digital and technology-driven skills, Harvard University has made several of its courses accessible online at no cost through its learning platform. The offerings span key areas ...

New program matches top researchers with expert service providers trained to offer a comprehensive suite of Shasta® ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 32% of the US adult population. The ...

A comprehensive guide to crypto programming in 2026, covering essential languages, smart contract development, DeFi applications ...

The PIS elicited a potent immune response as measured by local skin tests and immunological assays.

Privacy and ethics while matching data with locations were hot topics during Friday’s panel discussion on GIS technology and ...

Invivyd Inc. (NASDAQ:IVVD) is one of the best NASDAQ growth stocks to buy and hold forever. On April 9, Invivyd announced ...

AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering next-generation gene therapies for inherited retinal diseases (IRDs) has today announced its participation in the ...

Synopsys is working with EMA and Cesium, part of Bentley Systems, to test equipment functionality by virtually replicating ...

Accelsius, the leader in two-phase, direct-to-chip liquid cooling technology for AI and high-performance computing, today ...